Articles

Results from a phase 3 study of circularly permuted tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) + thalidomide and dexamethasone demonstrated this was a safe and effective treatment for patients with RRMM, including those with a poor prognosis. Read More ›

Talquetamab, a first-in-class bispecific antibody, showed encouraging efficacy with manageable toxicity in heavily pretreated patients with RRMM. An ongoing phase 2 investigation will determine the optimal dosing. Read More ›

Interim results from the STOMP study show that the combination of selinexor, pomalidomide, and dexamethasone appears to offer relatively high overall response rates and encouraging progression-free survival in heavily pretreated patients with multiple myeloma. Read More ›

The preliminary results of the phase 1b/2 CARTITUDE-1 study revealed that early, deep, and durable responses were demonstrated and that a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM was observed. Read More ›

Results from a first-in-human study of AMG 701, an anti-BCMA BiTE molecule, showed an acceptable safety profile, promising efficacy, and a favorable pharmacokinetic profile in heavily pretreated patients with RRMM, thereby supporting ongoing evaluation. Read More ›

The combination of selinexor, pomalidomide, and dexamethasone is efficacious, durable and safe in patients with RRMM. Read More ›

Adding daratumumab to lenalidomide, bortezomib, and dexamethasone induction and consolidation, followed by maintenance with lenalidomide ± daratumumab for transplant-eligible patients with NDMM elicits deep and improving responses, with no additional safety concerns upon longer follow-up. Read More ›

Results from a phase 2 study of isatuximab in previously treated patients with amyloid light-chain (AL) amyloidosis showed encouraging efficacy and a good safety profile. Read More ›

Although promising efficacy and acceptable toxicity were reported for belantamab mafodotin + pomalidomide + dexamethasone in patients with RRMM, the high rate of dose holds at the 2.5-mg/kg level warranted examination of alternative dosing schedules. Read More ›

Daratumumab + pomalidomide and dexamethasone reduced the risk for disease progression and death without additional safety signals versus pomalidomide and dexamethasone alone for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor. Read More ›